These findings, consistent with previous reports with IgE antibodies targeting other tumor-associated antigens such as CSPG4, SLC3A2 and FRα,15 16 20 39 confirmed the ability of anti-HER2 IgEs to engender a pro-inflammatory shift of monocytes, and point to a potential mechanism for Fc-meditated stimulation of antitumor immune conditions. The gene discussed is ERBB2; the disease is neoplasm.